STOCK PURCHASE AGREEMENT

 

EXHIBIT 10.56

[CERTAIN INFORMATION HAS BEEN OMITTED HEREIN PURSUANT TO A REQUEST 
FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2.  THE REDACTED 
MATERIAL HAS BEEN SEPARATELY FILED WITH THE COMMISSION.]

                       STOCK PURCHASE AGREEMENT
                       ------------------------

            THIS STOCK PURCHASE AGREEMENT (the "Agreement") is made 
as of the 1st day of May, 1996 by and between GENSIA, INC., a 
Delaware corporation (the "Company"), and PFIZER INC., a Delaware 
corporation (the "Investor").

            THE PARTIES HEREBY AGREE AS FOLLOWS:

            I.  PURCHASE AND SALE OF STOCK.

            1.1  Sale and Issuance of Common Stock.  Subject to the 
terms and conditions of this Agreement, Investor hereby purchases and 
the Company hereby sells and issues to Investor 792,293 shares (the 
"Original Shares") of the Company's Common Stock for the purchase 
price of 120% of the average Nasdaq closing price per share during 
the 20-day consecutive trading period ending five days prior to the 
date hereof (such average Nasdaq closing price is hereinafter 
referred to as the "Base Price" and such per share purchase price is 
hereinafter referred to as the "Per Share Purchase Price") for an 
aggregate of $5,000,002.66 (the "Purchase Price").

            1.2  Closing.  The purchase and sale of the Common Stock 
shall take place at the offices of the Company, 9360 Towne Centre 
Drive, San Diego, California, at 10 A.M., on the date hereof, or at 
such other times and places as the Company and Investor mutually 
agree upon, verbally or in writing (which times and places are 
designated as the "Closing").  At the Closing the Company shall 
deliver to Investor a certificate representing the Common Stock which 
such Investor is purchasing against delivery to the Company by such 
Investor of a bank wire in same day funds in the amount of the 
Purchase Price therefor payable to the Company's order.

            1.3 [CONFIDENTIAL TREATMENT REQUESTED]

            1.4   Definitions.

            (a)   The following terms, as used herein, have the 
following meanings:

            "Closing Date" means the date of the Closing.

            "Common Stock" means the Common Stock, par value $0.01 
per share of the Company, together with the associated preferred 
stock purchase rights established pursuant to the Rights Agreement 
dated March 9, 1992 between the Company and First Interstate Bank of 
California as rights agent (the "Rights").

            "Material Adverse Effect" means a material adverse effect 
on the condition (financial or otherwise), business, assets, results 
of operations of a corporation and its subsidiaries taken as a whole.

            "1934 Act" means the Securities Exchange Act of 1934, as 
amended, and the rules and regulations promulgated thereunder.

            "1933 Act" means the Securities Act of 1933, as amended, 
and the rules and regulations promulgated thereunder.

            "Person" shall mean an individual, corporation, 
partnership, trust, business trust, association, joint stock company, 
joint venture, pool, syndicate, sole proprietorship, unincorporated 
organization, governmental authority or any other form of entity not 
specifically listed herein.

            2.  REPRESENTATIONS AND WARRANTIES OF THE COMPANY.  The 
Company hereby represents and warrants to Investor that:

            2.1  ORGANIZATION, GOOD STANDING AND QUALIFICATION.  The 
Company is a corporation duly organized, validly existing and in good 
standing under the laws of the State of Delaware and has all 
requisite corporate power and authority to carry on its business as 
now conducted.  The Company is duly qualified to transact business 
and is in good standing in each jurisdiction in which the failure so 
to qualify would have a Material Adverse Effect.

            2.2  CAPITALIZATION.  The authorized capital of the 
Company consists of:

            (i)  PREFERRED STOCK.  5,000,000 shares of Preferred 
Stock, of which 1,840,000 shares have been designated $3.75 
Convertible Exchangeable Preferred Stock, par value $.01 per share 
(the "Convertible Preferred Stock"), and 100,000 shares have been 
designated Series I Participating Preferred Stock, par value $.01 per 
share (the "Participating Preferred Stock").  There are 1,600,000 
shares of Convertible Preferred Stock and no

- -2-

shares of Participating Preferred Stock, respectively, issued and 
outstanding.

            (ii)COMMON STOCK.  75,000,000 shares of Common Stock, of 
which 34,756,492 shares were issued and outstanding on February 29, 
1996.

            2.3  AUTHORIZATION.  All corporate action on the part of 
the Company, its officers, directors and stockholders necessary for 
(i) the authorization, execution and delivery of this Agreement, (ii) 
the performance of all obligations of the Company hereunder and (iii) 
the authorization, issuance (or reservation for issuance) and 
delivery of the Common Stock being sold hereunder, to the extent that 
the foregoing requires performance on or prior to the Closing, has 
been taken and this Agreement constitutes the valid and legally 
binding obligation of the Company, enforceable against the Company in 
accordance with its terms.

            2.4  VALID ISSUANCE OF COMMON STOCK.  The Common Stock 
purchased by the Investor hereunder has been duly and validly issued 
and is fully paid and nonassessable and, based in part upon the 
representations of the Investor in this Agreement, was issued in 
compliance with all applicable federal and state securities laws.

            2.5 COMPLIANCE WITH LAWS AND COURT ORDERS; NO DEFAULTS.

            (a)   The Company is not in violation of any applicable 
law, rule, regulation, judgment, injunction, order or decree except 
for violations that have not had and would not reasonably be expected 
to have, individually or in the aggregate, a Material Adverse Effect.

            (b)   The Company is not in default under, and no 
condition exists that with notice or lapse of time or both would 
constitute a default under, any agreement or other instrument binding 
upon the Company or any license, franchise, permit or similar 
authorization held by the Company, which defaults or potential 
defaults, individually or in the aggregate, would reasonably be 
expected to have a Material Adverse Effect.

            2.6  COMPLIANCE WITH OTHER INSTRUMENTS.  The Company is 
not in violation or default of any provisions of its Charter 
documents or Bylaws or of any judgment, order, writ or decree by 
which it is bound.  The Company is not in violation or default of any 
instrument or contract to which it is a party or by which it is bound 
or, to the best knowledge of its officers after reasonable inquiry, 
of any provision of any federal or state statute (including without 
limitation environmental and labor laws and filing requirements under 
the Employee Retirement Income Security Act of 1974), rule or 
regulation applicable to the Company, which violation or default 
would have a Material

- -3-

Adverse Effect.  The execution, delivery and performance of this 
Agreement and the consummation of the transactions contemplated 
hereby will not result in any such violation or be in conflict with 
or constitute, with or without the passage of time and giving of 
notice, either a default under any such provision, instrument, 
judgment, order, writ, decree or contract or an event which results 
in the creation of any material lien, charge or encumbrance upon any 
assets of the Company.

            3.  REPRESENTATIONS AND WARRANTIES OF INVESTOR.  This 
Agreement is made with Investor in reliance upon the Investor's 
representation and warranties to the Company, which by such 
Investor's execution of this Agreement the Investor hereby confirms, 
that:

            3.1  ORGANIZATION AND EXISTENCE.  Investor is a 
corporation duly incorporated, validly existing and in good standing 
under the laws of Delaware and has all corporate powers and all 
material governmental licenses, authorizations, permits, consents and 
approvals required to carry on its business as now conducted, except 
for those licenses, authorizations, permits, consents and approvals 
the absence of which would not, individually or in the aggregate, 
have a Material Adverse Effect.

            3.2  CORPORATE AUTHORIZATION.  This execution, delivery 
and performance by Investor of this Agreement are within the 
corporate powers of Investor and have been duly authorized by all 
necessary corporate action on the part of Investor.  This Agreement 
constitutes its valid and legally binding obligation, enforceable in 
accordance with its terms.

            3.3  PURCHASE ENTIRELY FOR OWN ACCOUNT.  The Common Stock 
to be received by Investor will be acquired for investment for 
Investor's own account, not as a nominee or agent, and not with a 
view to the resale or distribution of any part thereof, and that 
Investor has no present intention of selling, granting any 
participation in, or otherwise distributing the same.  By executing 
this Agreement, Investor further represents that Investor does not 
have any contract, undertaking, agreement or arrangement with any 
person to sell, transfer or grant participation to such person or to 
any third person, with respect to any of the Common Stock.

            3.4  CONFIDENTIALITY.  Investor hereby represents, 
warrants and covenants that it shall maintain in confidence, and 
shall not use or disclose without the prior written consent of the 
Company, any information identified as confidential that is furnished 
to it by the Company in connection with this Agreement.  This 
obligation of confidentiality shall not apply, however, to any 
information (a)in the public domain through no unauthorized act or 
failure to act by Investor, or (b)lawfully disclosed to the Investor 
by a third party who possessed such information without any 
obligation of confidentiality.  Investor

- -4-

further covenants that it shall return to the Company all tangible 
materials containing such information upon request by the Company.  
Investor agrees that it will restrict access to the Company's 
confidential information among its officers, directors and employees 
to those persons with a need to use such information.

            3.5  RESTRICTED SECURITIES.  Investor understands that 
the shares of Common Stock it is purchasing are characterized as 
"restricted securities" under the federal securities laws inasmuch as 
they are being acquired from the Company in a transaction not 
involving a public offering and that under such laws and applicable 
regulations such securities may be resold without registration under 
the 1933 Act, only in certain limited circumstances.  In this 
connection Investor represents that it is familiar with Securities 
and Exchange Commission ("SEC") Rule 144, as presently in effect, and 
understands the resale limitations imposed thereby and by the 1933 
Act.

            3.6  LEGENDS.  It is understood that the certificates 
evidencing the Common Stock may bear one or all of the following 
legends:

            (a)  "These securities have not been registered under the 
Securities Act of 1933.  They may not be sold, offered for sale, 
pledged or hypothecated in the absence of a registration statement in 
effect with respect to the securities under such Act or an opinion of 
counsel satisfactory to the Company that such registration is not 
required or unless sold pursuant to Rule 144 of such Act."

            (b)  If required by the authorities of any state in 
connection with the issuance or sale of the Common Stock the legend 
required by such state authority.

            4.  ADDITIONAL DELIVERIES TO INVESTOR AT CLOSING.  The 
obligations of Investor under Subsection  of this Agreement are 
subject to the fulfillment on or before the Closing of each of the 
following conditions, the waiver of which shall not be effective if 
such Investor does not consent in writing thereto:

            4.1  COMPLIANCE CERTIFICATE.  The President or a Vice 
President of the Company shall deliver to Investor at the Closing a 
certificate stating that there has been no material adverse change in 
the business, affairs, prospects, operations, properties, assets or 
condition of the Company since March 31, 1996 other than because of 
operating losses and changes in the ordinary course of business and 
other than as set forth in the Company's press release dated April 
29, 1996, a copy of which is attached hereto.

            4.2   SECRETARY'S CERTIFICATE.  The Secretary of the 
Company shall deliver to Investor at the Closing a certificate

- -5-

certifying that attached thereto are true and complete copies of each 
of the following documents:

            a.    Restated Certificate of Incorporation as in effect 
on the Closing Date, of the Company;

            b.    Bylaws, as amended as in effect on the Closing 
Date, of the Company; and

            c.    Copies of the resolutions of the Company's Board of 
Directors authorizing execution and delivery of this Agreement, the 
Collaborative Research Agreement and the License and Royalty 
Agreement (each of the latter two agreements being dated as of the 
date hereof between the parties hereto) and performance of the 
transactions contemplated herein and therein.

            4.3   HSR ACT.  If applicable, the waiting period under 
the Hart-Scott-Rodino Antitrust Improvements Act of 1976, including 
any extensions of said waiting period, shall have expired and any 
investigations relating to the transactions contemplated herein and 
in the Collaborative Research Agreement and the License and Royalty 
Agreement referred to in Subsection 4.2(c) of this Agreement that may 
have been opened by either the Department of Justice or the Federal 
Trade Commission (by means of a request for additional information or 
otherwise) shall have been terminated.

            5.    REGISTRATION RIGHTS.  The Company covenants and 
agrees as follows:

            5.1   CERTAIN ADDITIONAL DEFINITIONS.

            As used in this Agreement, the following capitalized 
terms shall have the following meanings:

            "PROSPECTUS" shall mean the prospectus included in any 
Registration Statement, as amended or supplemented by any prospectus 
supplement with respect to the terms of the offering of any portion 
of the Registrable Securities covered by such Registration Statement 
and by all other amendments and supplements to the prospectus, 
including post-effective amendments and all material incorporated by 
reference in such prospectus.

             "REGISTER," "REGISTERED" and "REGISTRATION" refer to a 
registration effected by preparing and filing a registration 
statement or similar document in compliance with the 1933 Act, and 
such registration statement or document becoming effective under the 
1933 Act.

            "REGISTRABLE SECURITIES" shall mean (i)the Common Stock 
of the Company purchased by the Investor pursuant to this Agreement; 
and (ii)any Common Stock of the Company issued as (or issuable upon 
the conversion or exercise of any warrant,

- -6-

right or other security which is issued as) a dividend or other 
distribution with respect to, or in exchange for or in replacement 
of, such Common Stock.

            "REGISTRATION STATEMENT" shall mean any registration 
statement of the Company that covers any of the Registrable 
Securities pursuant to the provisions of this Agreement, including 
the Prospectus, amendments and supplements to such Registration 
Statement, including post-effective amendments, all exhibits and all 
material incorporated by reference in such Registration Statement.

            5.2   REGISTRATION.  The Company will use its reasonable 
best efforts to effect a registration to permit the sale of the 
Registrable Securities as described below, and pursuant thereto the 
Company will:

            (a)   prepare and file by June 30, 1996, and use its 
reasonable best efforts to thereafter have declared effective by the 
SEC, a Registration Statement on Form S-3 relating to resale of all 
of the shares of the Registrable Securities and use its reasonable 
best efforts to cause such Registration Statement to remain 
continuously effective for a period which will terminate when all 
Registrable Securities covered by such Registration Statements, as 
amended from time to time, have been sold or when the Registrable 
Securities may be sold under Rule 144(k) under the 1933 Act.

            (b)   prepare and file with the SEC such amendments and 
post-effective amendments to the Registration Statement and the 
Prospectus as may be necessary to keep such Registration Statement 
effective for the period specified in Section 5.2(a) and to comply 
with the provisions of the 1933 Act and the 1934 Act with respect to 
the distribution of all Registrable Securities;

            (c)   notify the Investor, promptly, and confirm such 
notice in writing, (i) when the Prospectus or any supplement or post-
effective amendment has been filed, and, with respect to the 
Registration Statement or any post-effective amendment, when the same 
has become effective, (ii) of any request by the SEC for amendments 
or supplements to the Registration Statement or Prospectus or for 
additional information, (iii) of the issuance by the SEC of any stop 
order suspending the effectiveness of the Registration Statement or 
the initiation of any proceedings for that purpose, and (iv) of the 
receipt by the Company of any notification with respect to the 
suspension of the qualification of the Registrable Securities for 
sale in any jurisdiction or the initiation or threatening of any 
proceeding for such purpose;

            (d)   make every reasonable effort to obtain the 
withdrawal of any order suspending the effectiveness of the 
Registration Statement at the earliest possible moment;

- -7-

            (e)   furnish to the Investor, without charge, at least 
one copy of the Registration Statement and any post-effective 
amendment thereto, including financial statements and schedules, all, 
upon a Investor's request, documents incorporated therein by 
reference and all exhibits thereto (including those incorporated by 
reference);

            (f)   deliver to the Investor, without charge, as many 
copies of the Prospectus (including each preliminary prospectus) and 
any amendment or supplement thereto as it may reasonably request in 
order to facilitate the disposition of the Registrable Securities;

            (g)   cause all Registrable Securities covered by the 
Registration Statement to be listed on each securities exchange or 
market on which similar securities issued by the Company are then 
listed, and if the securities are not so listed to use its reasonable 
best efforts promptly to cause all such securities to be listed on 
either the New York Stock Exchange, the American Stock Exchange or 
the Nasdaq Stock Market;

            (h)   use reasonable best efforts to qualify or register 
the Registrable Securities for sale under (or obtain exemptions from 
the application of) the Blue Sky laws of such jurisdictions as are 
applicable.  The Company shall not be required to qualify as a 
foreign corporation or to file a general consent to service of 
process in any such jurisdiction where it is not presently qualified 
or where it would be subject to general service of process or 
taxation as a foreign corporation in any jurisdiction where it is not 
now so subject.

            (I)   otherwise use its reasonable best efforts to comply 
with all applicable rules and regulations of the SEC under the 1933 
Act and the 1934 Act and take such other actions as may be reasonably 
necessary to facilitate the registration of the Registrable 
Securities hereunder.

            Investor shall furnish to the Company such information 
regarding the distribution of such securities as the Company may from 
time to time reasonably request in writing.

            If at any time, the Company delivers a certificate in 
writing to the Investor, to the effect that a delay in the sale of 
Registrable Securities by the Investor under the Registration 
Statement is necessary because a sale pursuant to such Registration 
Statement in its then current form would reasonably be expected to 
constitute a violation of the federal securities laws the Investor 
shall agree not to sell or otherwise transfer such Registrable 
Securities for the period of time specified by the Company in its 
certificate.  In no event shall such delay exceed ten (10) business 
days; PROVIDED, HOWEVER, that if, prior to the expiration of such ten 
(10) business day period, the Company delivers a certificate in 
writing to the Investor to the effect that a further delay in such 
sale beyond such ten (10)

- -8-

business day period is necessary because a sale pursuant to such 
Registration Statement in its then current form would reasonably be 
expected to constitute a violation of the federal securities laws, 
the Company may refuse to permit the Investor to resell any 
Registrable Securities pursuant to such Registration Statement for an 
additional period not to exceed five (5) business days.

            5.3   Registration Expenses.  All expenses incident to 
the Company's performance of or compliance with this Agreement, 
including without limitation all registration and filing fees, fees 
with respect to the filings required to be made with the National 
Association of Securities Dealers, Inc., fees and expenses of 
compliance with the securities or blue sky laws, printing expenses, 
messenger, telephone and delivery expenses, fees and disbursements of 
counsel for the Company, fees and disbursements of all independent 
certified public accountants of the Company, fees and expenses 
incurred in connection with the listing of the securities, rating 
agency fees and the fees and expenses of any person, including 
special experts, retained by the Company, will be borne by the 
Company, regardless of whether the Registration Statement becomes 
effective; provided, however, that the Company will not be required 
to pay discounts, commissions or fees of underwriters, selling 
brokers, dealer managers or similar securities industry professionals 
relating to the distribution of the Registrable Securities or fees or 
disbursements of any other counsel to the Investor.

            5.4   Rule 144.

            The Company covenants that it will file the reports 
required to be filed by it under the 1933 Act and the 1934 Act and 
the rules and regulations thereunder, and it will take such further 
action as the Investor may reasonably request, all to the extent 
required to enable Investor to sell Registrable Securities without 
registration under the 1933 Act in reliance on the exemption provided 
by Rule 144 or Rule 144A under the 1933 Act or any successor or 
similar rules or statues.  Upon the request of the Investor, the 
Company will deliver to the Investor a written statement as to 
whether the Company has complied with such information and 
requirements.

            6.  MISCELLANEOUS.

            6.1  SUCCESSORS AND ASSIGNS.  The terms and conditions of 
this Agreement shall inure to the benefit of and be binding upon the 
respective permitted successors and assigns of the parties.  Nothing 
in this Agreement, express or implied, is intended to confer upon any 
party other than the parties hereto or their respective successors 
and assigns any rights, remedies, obligations, or liabilities under 
or by reason of this Agreement, except as expressly provided in this 
Agreement.

- -9-

            6.2  GOVERNING LAW.  This Agreement shall be governed by 
and construed under the laws of the State of California (irrespective 
of its choice of law principles).

            6.3  COUNTERPARTS.  This Agreement may be executed in two 
or more counterparts, each of which shall be deemed an original, but 
all of which together shall constitute one and the same instrument.

            6.4  TITLES AND SUBTITLES.  The titles and subtitles used 
in this Agreement are used for convenience only and are not to be 
considered in construing or interpreting this Agreement.

            6.5  NOTICES.  Unless otherwise provided, any notice 
required or permitted under this Agreement shall be given in writing 
and shall be deemed effectively given upon personal delivery to the 
party to be notified, or if sent by telex or telecopier, upon receipt 
of the correct answerback, or upon deposit with the United States 
Post Office, by registered or certified mail, or upon deposit with an 
overnight air courier, in each case postage prepaid and addressed to 
the party to be notified at the address as follows, or at such other 
address as such party may designate by ten days' advance written 
notice to the other party:

                  If to the Company:

                  Gensia, Inc.
                  9360 Towne Centre Drive
                  San Diego, CA 92121-3030
                  Attn: Secretary
                  Fax: (619) 453-0095

                       with a copy to:

                  Pillsbury Madison & Sutro
                  P.O. Box 7880
                  San Francisco, CA 94104
                  Attn:  Thomas E. Sparks, Esq.
                  Fax:  (415) 983-7396

                  If to the Investor:
                  Pfizer Inc.
                  235 East 42nd Street
                  New York, NY 10017
                  Attn: Office of the General Counsel
                  Fax:  

            6.6  FINDERS' FEE.  Each party represents that it neither 
is nor will be obligated for any finders' fee or commission in 
connection with this transaction.  Investor agrees to indemnify and 
hold harmless the Company from any liability for

- -10-

any commission or compensation in the nature of a finders' fee (and 
the costs and expenses of defending against such liability or 
asserted liability) for which the Investor or any of its officers, 
partners, employees or representatives is responsible.

            The Company agrees to indemnify and hold harmless 
Investor from any liability for any commission or compensation in the 
nature of a finders' fee (and the costs and expenses of defending 
against such liability or asserted liability) for which the Company 
or any of its officers, employees or representatives is responsible.

            6.7  EXPENSES.  The Company and the Investor shall pay 
their respective costs and expenses incurred with respect to the 
negotiation, execution, delivery and performance of this Agreement.  
If any action at law or in equity is necessary to enforce or 
interpret the terms of this Agreement, the prevailing party shall be 
entitled to reasonable attorneys' fees, costs and necessary 
disbursements in addition to any other relief to which such party may 
be entitled.

            6.8  AMENDMENTS AND WAIVERS.  Any term of this Agreement 
may be amended and the observance of any term of this Agreement may 
be waived (either generally or in a particular instance and either 
retroactively or prospectively), only with the written consent of the 
Company and the Investor.  Any amendment or waiver effected in 
accordance with this paragraph shall be binding upon each holder of 
any securities purchased under this Agreement at the time 
outstanding, each future holder of all such securities, and the 
Company.

            6.9  SEVERABILITY.  If one or more provisions of this 
Agreement are held to be unenforceable under applicable law, such 
provision shall be excluded from this Agreement and the balance of 
this Agreement shall be interpreted as if such provision were so 
excluded and shall be enforceable in accordance with its terms.

            6.10  ENTIRE AGREEMENT.  This Agreement, the 
Collaborative Research Agreement, and the License and Royalty 
Agreement, constitute the entire agreement between the parties with 
respect to the subject matter hereof and thereof and supersede all 
prior agreements and understandings, both oral and written, between 
the parties with respect to the subject matter hereof and thereof.  
No representation, inducement, promise, understanding, condition or 
warranty not set forth herein or therein has been made or relied upon 
by either party hereto.  Neither this Agreement nor any provision 
hereof is intended to confer upon any Person other than the parties 
hereto any rights or remedies hereunder.

- -11-

            IN WITNESS WHEREOF, the parties have executed this 
Agreement as of the date first above written.

                        GENSIA, INC.

                        By /s/ Paul K. Laikind
                           -----------------------------------------

                        Title Vice President, Corporate Development
                              --------------------------------------

                        PFIZER INC.

                        By /s/ George M. Milne
                           ---------------------

                        Title President, Central Research
                              ------------------------------

- -12- 

Basic Info X:

Name: STOCK PURCHASE AGREEMENT
Type: Stock Purchase Agreement
Date: Aug. 14, 1996
Company: SICOR INC
State: Delaware

Other info:

Date:

  • 1st day of May , 1996
  • March 9 , 1992
  • February 29 , 1996
  • March 31 , 1996
  • April 29 , 1996
  • June 30 , 1996

Organization:

  • Issuance of Common Stock
  • Closing the Company
  • First Interstate Bank of California
  • the State of Delaware
  • Convertible Exchangeable Preferred Stock
  • Material Adverse Effect
  • Securities and Exchange Commission
  • Company 's Board of Directors
  • Department of Justice
  • Federal Trade Commission
  • New York Stock Exchange
  • American Stock Exchange
  • Nasdaq Stock Market
  • National Association of Securities Dealers , Inc.
  • the State of California
  • United States Post Office
  • Gensia , Inc.
  • Towne Centre Drive
  • Pillsbury Madison & Sutro P.O
  • Collaborative Research Agreement

Location:

  • California
  • Delaware
  • San Diego
  • San Francisco
  • Esq
  • New York

Money:

  • $ 5,000,002.66
  • $ 0.01
  • $ 3.75
  • $ .01

Person:

  • Thomas E. Sparks
  • Paul K. Laikind
  • George M. Milne

Percent:

  • 120 %